Charles River Laboratories Intl

NYSE:CRL

美國 / 保健 / 生命科學工具和服務

綜觀

股息

5年歷史財務資料

股價

155.55 USD


Key Metrics	Latest
Total Revenue	4.05 B
Adjusted EBITDA	898.2 M
EBITDA Margin	22.2%
Net Profit Margin	6.5%
Total Assets	7.528 B
Total Debt	2.781 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	2,923.93	3,540.16	3,976.06	4,129.41	4,049.99	4,049.99	4,129.41	4,049.99
% Growth		0.21	0.12	0.04	(0.02)			(0.02)

Adjusted EBITDA	674.00	899.93	969.38	965.92	898.20	898.20	965.92	898.20
% Margin	0.23	0.25	0.24	0.23	0.22	0.22	0.23	0.22

Adjusted EBIT	439.08	634.39	665.51	651.79	545.86	545.86	651.79	545.86
% Margin	0.15	0.18	0.17	0.16	0.13	0.13	0.16	0.13

Adjusted Net Income	380.34	418.04	412.92	436.08	265.16	265.16	436.08	265.16
% Margin	0.13	0.12	0.10	0.11	0.07	0.07	0.11	0.07

Adjusted Basic EPS	7.68	8.31	8.13	8.51	5.16	5.16	8.51	5.16

支援算式

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	2,924	3,540	3,976	4,129	4,050	4,050	4,129	4,050
% Growth	NA	21.1%	12.3%	3.9%	-1.9%			-1.9%

Cost of Revenue	(1,850)	(2,203)	(2,508)	(2,600)	(2,642)	(2,642)	(2,600)	(2,642)
Gross Profit	1,074	1,337	1,468	1,529	1,408	1,408	1,529	1,408
% Revenue	36.7%	37.8%	36.9%	37.0%	34.8%	34.8%	37.0%	34.8%

Research and Development	0	0	0	0	0	0	0	0
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(523)	(578)	(656)	(740)	(724)	(724)	(740)	(724)
Other Inc / (Exp)	(18)	(205)	(131)	(76)	(474)	(474)	(76)	(474)
Total Operating Exp	(541)	(784)	(786)	(816)	(1,197)	(1,197)	(816)	(1,197)

Operating Income	533	554	681	713	211	211	713	211
% Revenue	18.2%	15.6%	17.1%	17.3%	5.2%	5.2%	17.3%	5.2%

Interest Expense	(86)	(73)	(59)	(132)	(118)	(118)	(132)	(118)
Pre-tax Income	447	481	623	581	93	93	581	93
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(82)	(82)	(130)	(101)	(68)	(68)	(101)	(68)
Net Income to Company	365	399	493	480	25	25	480	25
% Margin	12.5%	11.3%	12.4%	11.6%	0.6%	0.6%	11.6%	0.6%

Minority Interest in Earnings	(1)	(8)	(6)	(6)	(3)	(3)	(6)	(3)
Net Income to Stockholders	364	391	486	475	22	22	475	22

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	(12)	(12)	0	(12)

Net Income to Common	364	391	486	475	10	10	475	10
% Margin	12.5%	11.0%	12.2%	11.5%	0.3%	0.3%	11.5%	0.3%

As Reported
Basic EPS (Continuing Ops)	7.35	7.77	9.57	9.27	0.20	0.20	9.27	0.20
Diluted EPS (Continuing Ops)	7.20	7.60	9.48	9.22	0.20	0.20	9.22	0.20

WA Basic Shares Out.	49.55	50.29	50.81	51.23	51.38	51.38	51.23	51.38
WA Diluted Shares Out.	50.61	51.43	51.30	51.45	51.63	51.63	51.45	51.63

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	447	481	623	581	93	93	581	93
Addback: Net Interest Expense	86	73	59	132	118	118	132	118
Addback: Other Non Operating Expenses, Total	(114)	54	92	(1)	11	11	(1)	11
Addback: Depreciation & Amortization	235	266	304	314	352	352	314	352
Addback: Restructuring Charges	0	7	8	30	107	107	30	107
Addback: Merger / Acquisition Expenses	10	39	8	8	2	2	8	2
Addback: Goodwill Impairment	0	0	0	0	215	215	0	215
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	(20)	(123)	1	1	1	1	1
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	10	0	0	(99)	0	0	(99)	0
Adjusted EBITDA	674	900	969	966	898	898	966	898
% Margin	23.1%	25.4%	24.4%	23.4%	22.2%	22.2%	23.4%	22.2%

Adjusted EBIT	439	634	666	652	546	546	652	546
% Margin	15.0%	17.9%	16.7%	15.8%	13.5%	13.5%	15.8%	13.5%

Adjusted Net Income Reconciliation
Net Income to Company	365	399	493	480	25	25	480	25
Addback: Unusual Items	20	26	(108)	(60)	324	324	(60)	324
Less: Tax Benefit of Unusual Items (26%)	(5)	(7)	28	16	(84)	(84)	16	(84)
Adjusted Net Income	380	418	413	436	265	265	436	265
% Margin	13.0%	11.8%	10.4%	10.6%	6.5%	6.5%	10.6%	6.5%

載入錯誤

Charles River Laboratories Intl

NYSE:CRL

美國 / 保健 / 生命科學工具和服務

5年歷史財務資料